Received by email:

File: 2014-01-15 Press Release (final).docx

STELLAR BIOTECHNOLOGIES ADOPTS NEW SHAREHOLDER RIGHTS PLAN

PORT HUENEME, CA (January 15, 2014) -- Stellar Biotechnologies, Inc. (TSX-V: KLH) (U.S. OTC: SBOTF) ("Stellar" or the 
--->"Company") announces the adoption of a new shareholder rights plan (the "New Rights Plan") which will become effective
---> on February 14, 2014, concurrent with the termination of the current shareholder rights plan of Stellar.
The Company adopted both the original rights plan and the New Rights Plan to ensure, to the extent possible: (i) that 
--->all shareholders are treated fairly in connection with any takeover offer for the Company, and (ii) in the event of an
---> unsolicited bid, to ensure that the board of directors (the "Board") is provided with a sufficient period of time to 
--->evaluate unsolicited takeover bids and to explore and develop alternatives to maximize shareholder value.
Under the terms of the New Rights Plan, one right will be issued by the Company for each outstanding common share at t
--->he close of business on February 14, 2014, and for each common share issued in the future (subject to the terms of the
---> New Rights Plan). The rights issued under the New Rights Plan become exercisable only if an offeror acquires or annou
--->nces its intention to acquire 20% or more of the common shares of the Company without complying with the "Permitted Bi
--->d" provisions of the New Rights Plan or without the approval of the Board.
Permitted Bids must be made to all holders of common shares of Stellar by way of a takeover bid circular prepared in c
--->ompliance with applicable securities laws and, among other things, must be open for acceptance for a minimum of 60 day
--->s. If at the end of 60 days at least 50% of the outstanding common shares other than those owned by the offeror and ce
--->rtain related parties have been tendered and not withdrawn, the bidder may take up and pay for the shares but must ext
--->end the bid for a further 10 days to allow other shareholders to tender to the bid.
If a takeover bid does not meet the Permitted Bid requirements of the New Rights Plan, the rights will entitle Stellar
---> shareholders, excluding the shareholder or shareholders making the takeover bid, to purchase additional common shares
---> of the Company at a substantial discount to the market price of the common shares at that time.
The New Rights Plan is similar to the type of rights plans adopted by other Canadian incorporated public companies and
---> is substantially similar to the current shareholder rights plan. The New Rights Plan is not being adopted in response
---> to any actual or threatened takeover bid or other proposal from a third party to acquire control of the Company.
Stellar expects to seek shareholder approval and ratification of the New Rights Plan at its upcoming annual general an
--->d special meeting of shareholders to be held on February 13, 2014. If the New Rights Plan is not ratified at the meeti
--->ng, the New Rights Plan and all rights issued thereunder will terminate.
A copy of the New Rights Plan is available under Stellar's profile on SEDAR at www.sedar.com.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole
---> Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic mark
--->ets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious d
--->iseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is u
--->nique in its proprietary methods, facilities, and KLH technology.  We are committed to meeting the growing demand for 
--->commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based ac
--->tive immunotherapies. 
To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.  
Company Contacts:
Frank Oakes
President and CEO  Phone +1 (805) 488-2800
investorrelations@stellarbiotech.com   Mark A. McPartland Vice President of Corporate Development and Communications P
--->hone: +1 (805) 488-2800 markmcp@stellarbiotech.com www.stellarbiotech.com   Forward Looking Statements
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future even
--->ts could differ materially from those anticipated in such statements. Readers should not place undue reliance on such 
--->statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to up
--->date any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news
---> release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities se
--->t out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United Stat
--->es. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the 
--->TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.